DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Provera (Medroxyprogesterone Acetate) - Published Studies

 
 



Provera Related Published Studies

Well-designed clinical trials related to Provera (Medroxyprogesterone)

Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. [2014]

A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania. [2014]

Differential effects of estrogen and micronized progesterone or medroxyprogesterone acetate on cognition in postmenopausal women. [2011.08]

Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. [2011.03.01]

Differential effects of estrogen and micronized progesterone or medroxyprogesterone acetate on cognition in postmenopausal women. [2011]

Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. [2010.09]

Vaginal estrogen supplementation during Depo-Provera initiation: a randomized controlled trial. [2010.09]

Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial. [2010.08]

Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial. [2010.06]

Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated equine estrogen after premenopausal hysterectomy with bilateral ovariectomy. [2010.05]

Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. [2010.02]

Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated equine estrogen after premenopausal hysterectomy with bilateral ovariectomy. [2010]

[Effects and safety of gonadotrophin-releasing hormone agonist combined with estradiol patch and oral medroxyprogesterone acetate on endometriosis] [2009.07]

Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome. [2009.04]

Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study. [2009.01]

Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause. [2009]

Interval of injections of intramuscular depot medroxyprogesterone acetate in the long-term treatment of endometriosis-associated pain: a randomized comparative trial. [2009]

Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. [2008.10]

Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users. [2008.09]

Effects in postmenopausal women of estradiol and medroxyprogesterone alone and combined on resistance artery function and endothelial morphology and movement. [2008.05]

Synchronization of follicular wave emergence in the seasonally anestrous ewe: the effects of estradiol with or without medroxyprogesterone acetate. [2008.04.15]

Estrogen, medroxyprogesterone acetate, endothelial function, and biomarkers of cardiovascular risk in young women. [2008.04]

Association between caffeine intake and bone mass among young women: potential effect modification by depot medroxyprogesterone acetate use. [2008.04]

Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers. [2008]

The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors. [2008]

Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users. [2007.12.21]

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. [2007.12.01]

A comparative study of Cyclofem and depot medroxyprogesterone acetate (DMPA) effects on endometrial vasculature. [2007.10]

Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trial. [2007.08]

Effect of three doses of conjugated estrogens/medroxyprogesterone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study. [2007.08]

Effect of mifepristone on endometrial matrix metalloproteinase expression and leukocyte abundance in new medroxyprogesterone acetate users. [2007.07]

Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study. [2007.06]

Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. [2007.05]

Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. [2007.03]

Mifepristone alters expression of endometrial steroid receptors and their cofactors in new users of medroxyprogesterone acetate. [2007.01]

[Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol] [2007]

Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. [2006.11]

Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. [2006.11]

Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. [2006.10]

Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. [2006.10]

Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. [2006.09]

Differential prevalence of quality-of-life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. [2006.06]

Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. [2006.03.20]

The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. [2006.03]

Effects of mifepristone on proliferation and apoptosis of human endometrium in new users of medroxyprogesterone acetate. [2006.03]

Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. [2006.02.20]

Conjugated estrogen plus medroxyprogesterone does not impair blood rheological properties in hypertensive postmenopausal women. [2006.02.20]

Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. [2006.02]

Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. [2006.01]

Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia menopause (PAM) study. [2005.11]

Effect of oral conjugated equine estrogen combined with medroxyprogesterone acetate on plasma homocysteine levels in postmenopausal women. [2005.10]

Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study. [2005.09.16]

Randomized assignment to copper IUD or depot-medroxyprogesterone acetate: feasibility of enrollment, continuation and disease ascertainment. [2005.09]

Concentration of depot medroxyprogesterone acetate and pain scores in adolescents: a randomized clinical trial. [2005.08]

Effect on sexual life--a comparison between tibolone and continuous combined conjugated equine estrogens and medroxyprogesterone acetate. [2005.04]

Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. [2005.04]

In vivo assessment of the regulation of transforming growth factor alpha, epidermal growth factor (EGF), and EGF receptor in the human endometrium by medroxyprogesterone acetate. [2005.01]

Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. [2005.01]

Well-designed clinical trials possibly related to Provera (Medroxyprogesterone)

Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. [2014]

Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial. [2014]

Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy. [2014]

Evaluation of contextual and demographic factors on licorice effects on reducing hot flashes in postmenopause women. [2014]

Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. [2013]

Progesterone increases resistance of ophthalmic and central retinal arteries in climacteric women. [2013]

Estrogen plus progestin and colorectal cancer incidence and mortality. [2012]

Breast cancer risk during hormone therapy: experimental versus clinical data. [2012]

Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. [2011.10.05]

Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial. [2011.10]

Vasomotor hot flashes and heart rate variability: a placebo-controlled trial of postmenopausal hormone therapy. [2011.09.19]

Steroidal contraceptives: effect on bone fractures in women. [2011.07.06]

Strategies to improve adherence and acceptability of hormonal methods of contraception. [2011.04.13]

Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial. [2011]

Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status. [2010.12]

The effects of a low therapeutic dose of betaCG fragment-lytic peptide conjugates on ovarian function and gonadotropin secretion in ewes: a randomized controlled trial. [2010.11]

Clinical trials in male hormonal contraception. [2010.11]

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. [2010.10.20]

Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials. [2010.10.11]

Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy. [2010.10]

Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension. [2010.07]

Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization. [2010.07]

Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy. [2010.07]

Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status. [2010.06.24]

Copper containing intra-uterine devices versus depot progestogens for contraception. [2010.06.16]

Effectiveness of hormone therapy for treating dry eye syndrome in postmenopausal women: a randomized trial. [2010.06]

Comparative effects of continuous combined hormone therapy and tibolone on body composition in postmenopausal women. [2010.06]

Effect of dienogest on estrogen-induced nitric oxide production in human umbilical vein endothelial cells and endothelium-dependent vasodilatation in postmenopausal women. [2010.05]

The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin levels in healthy postmenopausal women. [2010.05]

Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia. [2010.04]

[Effects of Kuntai Capsule and hormone replacement therapy on cognitive function and mental symptoms of early postmenopausal women: a randomized controlled trial] [2010.04]

Hormone therapy and physical function change among older women in the Women's Health Initiative: a randomized controlled trial. [2010.03]

Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. [2010.02.16]

Association of polymorphisms in genes involved in lipoprotein metabolism with plasma concentrations of remnant lipoproteins and HDL subpopulations before and after hormone therapy in postmenopausal women. [2010.02]

Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. [2010]

Striking increases in carotid artery wall thickness in healthy subjects. [2010]

Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy. [2010]

Submaximal exercise coronary artery flow increases in postmenopausal women without coronary artery disease after estrogen and atorvastatin. [2010]

Menopausal hormone therapy, hormone receptor status, and lung cancer in women. [2009.12]

Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. [2009.12]

Brain volumes, cognitive impairment, and conjugated equine estrogens. [2009.12]

Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. [2009.11]

Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. [2009.11]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017